Leukotuximab
Leukotuximab (ART-140; EGX-040) is an anti-JL1 mAb and an anti-leukemic agent. Leukotuximab targets the JL1 epitope of CD43 and exerts cytotoxic effects on JL1-positive leukemia cells. Except for thymocytes and some bone marrow mononuclear cells, Leukotuximab causes no damage to most normal tissues. Leukotuximab can be used in the research of acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.
For research use only. We do not sell to patients.
- Purity : 99.9%
- Molecular Weight:146.36 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Target
CD43/Leukosialin
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD43 Protein, Human (HEK293, HY-P77887) can bind Leukotuximab. The ED50 for this effect is 214 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 146.36 kDa
-
Color Colorless to light yellow
-
SMILES
[Leukotuximab]
-
Synonyms
ART-140; DNP-001; EGX-040
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)